Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective: To test the hypotheses predicted in a hypothetical model of Alzheimer disease (AD) biomarkers that rates of β-amyloid (Aβ) accumulation on PET imaging are not related to hippocampal neurodegeneration whereas rates of neurodegenerative brain atrophy depend on the presence of both amyloid and neurodegeneration in a population-based sample.
Methods: A total of 252 cognitively normal (CN) participants from the Mayo Clinic Study of Aging had 2 or more serial visits with both amyloid PET and MRI. Subjects were classified into 4 groups based on baseline positive/negative amyloid PET (A+ or A−) and baseline hippocampal volume (N+ or N−). We compared rates of amyloid accumulation and rates of brain atrophy among the 4 groups.
Results: At baseline, 148 (59%) were amyloid negative and neurodegeneration negative (A−N−), 29 (12%) amyloid negative and neurodegeneration positive (A−N+), 56 (22%) amyloid positive and neurodegeneration negative (A+N−), and 19 (8%) amyloid positive and neurodegeneration positive (A+N+). High rates of Aβ accumulation were found in those with abnormal amyloid at baseline and were not influenced by hippocampal neurodegeneration at baseline. In contrast, rates of brain atrophy were greatest in A+N+.
Conclusions: We describe a 2-feature biomarker approach to classifying elderly CN subjects that is complementary to the National Institute on Aging–Alzheimer's Association preclinical staging criteria. Our results support 2 key concepts in a model of the temporal evolution of AD biomarkers. First, the rate of Aβ accumulation is not influenced by neurodegeneration and thus may be a biologically independent process. Second, Aβ pathophysiology increases or catalyzes neurodegeneration.
GLOSSARY
- Aβ=
- β-amyloid;
- AD=
- Alzheimer disease;
- CN=
- cognitively normal;
- FDG=
- fluorodeoxyglucose;
- HVa=
- total intracranial volume–adjusted hippocampal volume;
- MCI=
- mild cognitive impairment;
- MCSA=
- Mayo Clinic Study of Aging;
- MPRAGE=
- magnetization-prepared rapid gradient echo;
- NFT=
- neurofibrillary tangle;
- NIA-AA=
- National Institute on Aging–Alzheimer's Association;
- ROI=
- region of interest;
- SNAP=
- suspected non-Alzheimer pathophysiology;
- SUVR=
- standardized uptake value ratio;
- TIV=
- total intracranial volume
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the article. The Article Processing Charge was paid by NIH RO1 AG041851.
Editorial, page 1576
- Received September 3, 2013.
- Accepted in final form January 7, 2014.
- © 2014 American Academy of Neurology
This is an open access article distributed under the terms of the Creative Commons Attribution-Noncommercial No Derivative 3.0 License, which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Hastening the Diagnosis of Amyotrophic Lateral Sclerosis
Dr. Brian Callaghan and Dr. Kellen Quigg
► Watch
Related Articles
Topics Discussed
Alert Me
Recommended articles
-
Article
Amyloid-first and neurodegeneration-first profiles characterize incident amyloid PET positivityClifford R. Jack, Jr, Heather J. Wiste, Stephen D. Weigand et al.Neurology, October 16, 2013 -
Articles
Short-term clinical outcomes for stages of NIA-AA preclinical Alzheimer diseaseD.S. Knopman, C.R. Jack, Jr., H.J. Wiste et al.Neurology, May 02, 2012 -
Articles
Hippocampal atrophy rates in Alzheimer diseaseAdded value over whole brain volume measuresW.J.P. Henneman, J. D. Sluimer, J. Barnes et al.Neurology, March 16, 2009 -
Article
Brain β-amyloid load approaches a plateauClifford R. Jack, Jr, Heather J. Wiste, Timothy G. Lesnick et al.Neurology, February 27, 2013